The DNAm-based models generated may improve risk stratification for short-term cardiovascular events in individuals with T2DM, providing a promising approach to refine identification of those at increased risk of MACE.
Abstract
Objective
Cardiovascular complications are the leading cause of death in type 2 diabetes mellitus (T2DM). We investigated whether blood-based DNA methylation (DNAm) biomarkers could improve risk stratification for major adverse cardiovascular events (MACE) in individuals with T2DM. RESEARCH
Design
AND
Methods
Epigenome-wide DNAm was profiled in peripheral blood mononuclear cells obtained at baseline from 305 T2DM participants of the Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial (TOSCA.IT) study, including 81 who experienced MACE within 5 years (T2DMACE) and 224 who did not (T2D). The population was randomly divided into training and internal test sets for model development and evaluation. Differential DNAm analyses were performed under five frameworks differing by covariate adjustment. Binomial least absolute shrinkage and selection operator (LASSO) logistic regression with stability selection was used to generate DNAm-based models to stratify individuals at higher risk of incident MACE over 5 years.
Results
Differential DNAm analysis identified 23,839, 21,529, 21,500, 12,114, and 7,101 differentially methylated CpG sites across the five analytical frameworks. LASSO logistic regression was used to develop five DNAm-based models. Stability selection retained 22–26 CpG predictors per model. When evaluated in the internal test cohort, the five models showed high discriminative performance, with receiver operating characteristic area under the curve values ranging from 0.915 to 0.937 and area under the precision-recall curve values from 0.866 to 0.940. Several CpGs were independently associated with either increased or decreased risk of MACE, including 12 CpGs identified across all of the models.
Conclusions
The DNAm-based models we have generated may improve risk stratification for short-term cardiovascular events in individuals with T2DM, providing a promising approach to refine identification of those at increased risk of MACE.
DNA methylation-based signatures were associated with incident ASCVD and modestly improved risk prediction beyond that of traditional risk factors, and an agnostic probe reliability-based approach was developed.
A. Barad, D. Khodasevich, P. F. Kho et al.· medRxiv· 0 citations
Genomic analysis presented convincing evidence supporting the association between genetically predicted smoking initiation and an increased susceptibility to type 2 diabetes, highlighting the role of epigenetic DNA methylation.
Wenhua Li, Yixiao Li, Pan Dong et al.· Tobacco Induced Diseases· 0 citations
Epigenetic characteristics of cfDNA are closely associated with the severity of cardiac dysfunction in CVD patients and may serve as effective noninvasive molecular markers for cardiac function stratification and risk prediction accuracy.
S. Cai, Qingyuan Cai, Chunwen Jia· American journal of translat...· 0 citations
DNAmScore identified residual biological risk beyond PREVENT-like clinical predictors, with strong independent mortality associations and modest, consistent improvements in cross-fitted prediction performance, which support development and external validation of CVD-specific DNAm biomarkers.
D.-G. Xing, M. S. Bhuiyan, S. Conrad et al.· medRxiv· 0 citations
In participants with T2D and LFI, adding a metabolomic signature to SCORE2-Diabetes produced a statistically significant but moderate improvement in risk discrimination, which supports further evaluation in independent cohorts and prospective impact studies.
Mei-Li Li, Yan-Yan Shen, You-Wei Huang et al.· Frontiers in Endocrinology· 0 citations
An LE8-derived DNAm score was associated with lower cIMT across the life course and, to a lesser extent, across generations, suggesting that blood DNAm reflects cumulative cardiovascular health and vascular burden and may complement conventional cardiovascular risk assessment.
B. Mishra, E. Raitoharju, L.-P. LyytikaÌinen et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.